On 12 Nov 2026 Labcorp closed at $372.32, +49.5% this year; market cap $30.38bn, P/E 30.3.
Health Care · Health Care Services · NYSE · United States
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
| Market cap | $30.38bn |
| P/E (trailing) | 30.3 |
| EPS (TTM) | $12.30 |
| Beta | 0.83 |
| Dividend | $2.88 |
| Dividend yield | 0.77% |
| Ex-dividend date | 24 Nov 2026 |
| Latest report | 28 Oct 2026 |
| Next earnings | 26 Jan 2027 |
| YTD | +49.5% |
| 1Y | +41.4% |
| 3Y | +23.4% |
| 5Y | +9.0% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $13.95bn | $876.50m | $1.21bn |
| 2024 | $13.01bn | $746.00m | $1.10bn |
| 2023 | $12.16bn | $418.00m | $874.10m |
| 2022 | $11.86bn | $1.28bn | $1.47bn |
| 2021 | $13.14bn | $2.38bn | $2.65bn |
We publish no single base value for Labcorp. Our valuation methods put it between $227.21 and $315.05 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.